Cools J, DeAngelo DJ, Gotlib J, Stover EH, Legare RD, Cortes J, Kutok J, Clark J, Galinsky I, Griffin JD: A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med. 2003, 348: 1201-1214. 10.1056/NEJMoa025217
Article
CAS
PubMed
Google Scholar
Cools J, Stover EH, Boulton CL, Gotlib J, Legare RD, Amaral SM, Curley DP, Duclos N, Rowan R, Kutok JL: PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRalpha-induced myeloproliferative disease. Cancer Cell. 2003, 3: 459-469. 10.1016/S1535-6108(03)00108-9
Article
CAS
PubMed
Google Scholar
Martin-Broto J, Rubio L, Alemany R, Lopez-Guerrero JA: Clinical implications of KIT and PDGFRA genotyping in GIST. Clin Transl Oncol. 2010, 12: 670-676. 10.1007/s12094-010-0576-7
Article
CAS
PubMed
Google Scholar
Tefferi A, Vardiman JW: Classification and diagnosis of myeloproliferative neoplasms: the World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia. 2008, 2008 (22): 14-22.
Article
Google Scholar
Griffin JH, Leung J, Bruner RJ, Caligiuri MA, Briesewitz R: Discovery of a fusion kinase in EOL-1 cells and idiopathic hypereosinophilic syndrome. Proc Natl Acad Sci U S A. 2003, 100: 7830-7835. 10.1073/pnas.0932698100
Article
CAS
PubMed
PubMed Central
Google Scholar
Metzgeroth G, Schwaab J, Gosenca D, Fabarius A, Haferlach C, Hochhaus A, Cross NC, Hofmann WK, Reiter A: Long-term follow-up of treatment with imatinib in eosinophilia-associated myeloid/lymphoid neoplasms with PDGFR rearrangements in blast phase. Leukemia. 2013, 27: 2254-2256. 10.1038/leu.2013.129
Article
CAS
PubMed
Google Scholar
Lierman E, Michaux L, Beullens E, Pierre P, Marynen P, Cools J, Vandenberghe P: FIP1L1-PDGFRalpha D842V, a novel panresistant mutant, emerging after treatment of FIP1L1-PDGFRalpha T674I eosinophilic leukemia with single agent sorafenib. Leukemia. 2009, 23: 845-851. 10.1038/leu.2009.2
Article
CAS
PubMed
Google Scholar
Jin Y, Chen Q, Lu Z, Chen B, Pan J: Triptolide abrogates oncogene FIP1L1-PDGFRalpha addiction and induces apoptosis in hypereosinophilic syndrome. Cancer Sci. 2009, 100: 2210-2217. 10.1111/j.1349-7006.2009.01283.x
Article
CAS
PubMed
Google Scholar
Pan J, Quintas-Cardama A, Manshouri T, Giles FJ, Lamb P, Tefferi A, Cortes J, Kantarjian H, Verstovsek S: The novel tyrosine kinase inhibitor EXEL-0862 induces apoptosis in human FIP1L1-PDGFR-alpha-expressing cells through caspase-3-mediated cleavage of Mcl-1. Leukemia. 2007, 21: 1395-1404. 10.1038/sj.leu.2404714
Article
CAS
PubMed
Google Scholar
Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, Sawyers CL: Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science. 2001, 293: 876-880. 10.1126/science.1062538
Article
CAS
PubMed
Google Scholar
Azam M, Seeliger MA, Gray NS, Kuriyan J, Daley GQ: Activation of tyrosine kinases by mutation of the gatekeeper threonine. Nat Struct Mol Biol. 2008, 15: 1109-1118. 10.1038/nsmb.1486
Article
CAS
PubMed
PubMed Central
Google Scholar
von Bubnoff N, Sandherr M, Schlimok G, Andreesen R, Peschel C, Duyster J: Myeloid blast crisis evolving during imatinib treatment of an FIP1L1-PDGFR alpha-positive chronic myeloproliferative disease with prominent eosinophilia. Leukemia. 2005, 19: 286-287. 10.1038/sj.leu.2403600
Article
CAS
PubMed
Google Scholar
Lierman E, Folens C, Stover EH, Mentens N, Van Miegroet H, Scheers W, Boogaerts M, Vandenberghe P, Marynen P, Cools J: Sorafenib is a potent inhibitor of FIP1L1-PDGFRalpha and the imatinib-resistant FIP1L1-PDGFRalpha T674I mutant. Blood. 2006, 108: 1374-1376. 10.1182/blood-2006-02-004457
Article
CAS
PubMed
PubMed Central
Google Scholar
Metzgeroth G, Erben P, Martin H, Mousset S, Teichmann M, Walz C, Klippstein T, Hochhaus A, Cross NC, Hofmann WK, Reiter A: Limited clinical activity of nilotinib and sorafenib in FIP1L1-PDGFRA positive chronic eosinophilic leukemia with imatinib-resistant T674I mutation. Leukemia. 2012, 26: 162-164. 10.1038/leu.2011.181
Article
CAS
PubMed
Google Scholar
O'Hare T, Shakespeare WC, Zhu X, Eide CA, Rivera VM, Wang F, Adrian LT, Zhou T, Huang WS, Xu Q: AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell. 2009, 16: 401-412. 10.1016/j.ccr.2009.09.028
Article
CAS
PubMed
PubMed Central
Google Scholar
Weisberg E, Choi HG, Ray A, Barrett R, Zhang J, Sim T, Zhou W, Seeliger M, Cameron M, Azam M: Discovery of a small-molecule type II inhibitor of wild-type and gatekeeper mutants of BCR-ABL, PDGFRalpha, Kit, and Src kinases: novel type II inhibitor of gatekeeper mutants. Blood. 2010, 115: 4206-4216. 10.1182/blood-2009-11-251751
Article
CAS
PubMed
PubMed Central
Google Scholar
Chan WW, Wise SC, Kaufman MD, Ahn YM, Ensinger CL, Haack T, Hood MM, Jones J, Lord JW, Lu WP: Conformational Control Inhibition of the BCR-ABL1 Tyrosine Kinase, Including the Gatekeeper T315I Mutant, by the Switch-Control Inhibitor DCC-2036. Cancer Cell. 2011, 19: 556-568. 10.1016/j.ccr.2011.03.003
Article
CAS
PubMed
PubMed Central
Google Scholar
Eide CA, Adrian LT, Tyner JW, Mac Partlin M, Anderson DJ, Wise SC, Smith BD, Petillo PA, Flynn DL, Deininger MW: The ABL Switch Control Inhibitor DCC-2036 Is Active against the Chronic Myeloid Leukemia Mutant BCR-ABLT315I and Exhibits a Narrow Resistance Profile. Cancer Res. 2011, 71: 3189-3195. 10.1158/0008-5472.CAN-10-3224
Article
CAS
PubMed
PubMed Central
Google Scholar
Huang WS, Metcalf CA, Sundaramoorthi R, Wang Y, Zou D, Thomas RM, Zhu X, Cai L, Wen D, Liu S: Discovery of 3-[2-(imidazo[1, 2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpipera zin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a potent, orally active pan-inhibitor of breakpoint cluster region-abelson (BCR-ABL) kinase including the T315I gatekeeper mutant. J Med Chem. 2010, 53: 4701-4719. 10.1021/jm100395q
Article
CAS
PubMed
Google Scholar
Gozgit JM, Wong MJ, Wardwell S, Tyner JW, Loriaux MM, Mohemmad QK, Narasimhan NI, Shakespeare WC, Wang F, Druker BJ: Potent activity of ponatinib (AP24534) in models of FLT3-driven acute myeloid leukemia and other hematologic malignancies. Mol Cancer Ther. 2011, 10: 1028-1035. 10.1158/1535-7163.MCT-10-1044
Article
CAS
PubMed
PubMed Central
Google Scholar
Zhou T, Commodore L, Huang WS, Wang Y, Thomas M, Keats J, Xu Q, Rivera VM, Shakespeare WC, Clackson T: Structural mechanism of the Pan-BCR-ABL inhibitor ponatinib (AP24534): lessons for overcoming kinase inhibitor resistance. Chem Biol Drug Des. 2011, 77: 1-11. 10.1111/j.1747-0285.2010.01054.x
Article
CAS
PubMed
Google Scholar
Aichberger KJ, Mayerhofer M, Gleixner KV, Krauth MT, Gruze A, Pickl WF, Wacheck V, Selzer E, Mullauer L, Agis H: Identification of MCL1 as a novel target in neoplastic mast cells in systemic mastocytosis: inhibition of mast cell survival by MCL1 antisense oligonucleotides and synergism with PKC412. Blood. 2007, 109: 3031-3041.
Article
CAS
PubMed
Google Scholar
Rahmani M, Davis EM, Bauer C, Dent P, Grant S: Apoptosis induced by the kinase inhibitor BAY 43–9006 in human leukemia cells involves down-regulation of Mcl-1 through inhibition of translation. J Biol Chem. 2005, 280: 35217-35227. 10.1074/jbc.M506551200
Article
CAS
PubMed
Google Scholar
Clohessy JG, Zhuang J, Brady HJ: Characterisation of Mcl-1 cleavage during apoptosis of haematopoietic cells. Br J Haematol. 2004, 125: 655-665. 10.1111/j.1365-2141.2004.04949.x
Article
CAS
PubMed
Google Scholar
Reya T, Clevers H: Wnt signalling in stem cells and cancer. Nature. 2005, 434: 843-850. 10.1038/nature03319
Article
CAS
PubMed
Google Scholar
Coluccia AM, Vacca A, Dunach M, Mologni L, Redaelli S, Bustos VH, Benati D, Pinna LA, Gambacorti-Passerini C: Bcr-Abl stabilizes beta-catenin in chronic myeloid leukemia through its tyrosine phosphorylation. EMBO J. 2007, 26: 1456-1466. 10.1038/sj.emboj.7601485
Article
CAS
PubMed
PubMed Central
Google Scholar
Kajiguchi T, Lee S, Lee MJ, Trepel JB, Neckers L: KIT regulates tyrosine phosphorylation and nuclear localization of beta-catenin in mast cell leukemia. Leuk Res. 2008, 32: 761-770. 10.1016/j.leukres.2007.08.023
Article
CAS
PubMed
Google Scholar
Tickenbrock L, Schwable J, Wiedehage M, Steffen B, Sargin B, Choudhary C, Brandts C, Berdel WE, Muller-Tidow C, Serve H: Flt3 tandem duplication mutations cooperate with Wnt signaling in leukemic signal transduction. Blood. 2005, 105: 3699-3706. 10.1182/blood-2004-07-2924
Article
CAS
PubMed
Google Scholar
Semenov MV, Habas R, Macdonald BT, He X: SnapShot: Noncanonical Wnt Signaling Pathways. Cell. 2007, 131: 1378-
Article
PubMed
Google Scholar
Behrens J, von Kries JP, Kuhl M, Bruhn L, Wedlich D, Grosschedl R, Birchmeier W: Functional interaction of beta-catenin with the transcription factor LEF-1. Nature. 1996, 382: 638-642. 10.1038/382638a0
Article
CAS
PubMed
Google Scholar
Yu H, Pardoll D, Jove R: STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer. 2009, 9: 798-809. 10.1038/nrc2734
Article
CAS
PubMed
PubMed Central
Google Scholar
Domina AM, Vrana JA, Gregory MA, Hann SR, Craig RW: MCL1 is phosphorylated in the PEST region and stabilized upon ERK activation in viable cells, and at additional sites with cytotoxic okadaic acid or taxol. Oncogene. 2004, 23: 5301-5315. 10.1038/sj.onc.1207692
Article
CAS
PubMed
Google Scholar
Huber S, Oelsner M, Decker T, Zum Buschenfelde CM, Wagner M, Lutzny G, Kuhnt T, Schmidt B, Oostendorp RA, Peschel C, Ringshausen I: Sorafenib induces cell death in chronic lymphocytic leukemia by translational downregulation of Mcl-1. Leukemia. 2011, 25: 838-847. 10.1038/leu.2011.2
Article
CAS
PubMed
Google Scholar
Michels J, O'Neill JW, Dallman CL, Mouzakiti A, Habens F, Brimmell M, Zhang KY, Craig RW, Marcusson EG, Johnson PW, Packham G: Mcl-1 is required for Akata6 B-lymphoma cell survival and is converted to a cell death molecule by efficient caspase-mediated cleavage. Oncogene. 2004, 23: 4818-4827. 10.1038/sj.onc.1207648
Article
CAS
PubMed
Google Scholar
Shah NP, Kasap C, Weier C, Balbas M, Nicoll JM, Bleickardt E, Nicaise C, Sawyers CL: Transient potent BCR-ABL inhibition is sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosis. Cancer Cell. 2008, 14: 485-493. 10.1016/j.ccr.2008.11.001
Article
CAS
PubMed
Google Scholar
Gomez-Bougie P, Bataille R, Amiot M: The imbalance between Bim and Mcl-1 expression controls the survival of human myeloma cells. Eur J Immunol. 2004, 34: 3156-3164. 10.1002/eji.200424981
Article
CAS
PubMed
Google Scholar
Castellone MD, De Falco V, Rao DM, Bellelli R, Muthu M, Basolo F, Fusco A, Gutkind JS, Santoro M: The beta-catenin axis integrates multiple signals downstream from RET/papillary thyroid carcinoma leading to cell proliferation. Cancer Res. 2009, 69: 1867-1876. 10.1158/0008-5472.CAN-08-1982
Article
CAS
PubMed
PubMed Central
Google Scholar
Lierman E, Smits S, Cools J, Dewaele B, Debiec-Rychter M, Vandenberghe P: Ponatinib is active against imatinib-resistant mutants of FIP1L1-PDGFRA and KIT, and against FGFR1-derived fusion kinases. Leukemia. 2012, 26: 1693-1695. 10.1038/leu.2012.8
Article
CAS
PubMed
Google Scholar
Cortes JE, Kantarjian H, Shah NP, Bixby D, Mauro MJ, Flinn I, O'Hare T, Hu S, Narasimhan NI, Rivera VM: Ponatinib in refractory Philadelphia chromosome-positive leukemias. N Engl J Med. 2012, 367: 2075-2088. 10.1056/NEJMoa1205127
Article
CAS
PubMed
PubMed Central
Google Scholar
Jin Y, Lu Z, Ding K, Li J, Du X, Chen C, Sun X, Wu Y, Zhou J, Pan J: Antineoplastic mechanisms of niclosamide in acute myelogenous leukemia stem cells: inactivation of the NF-kappaB pathway and generation of reactive oxygen species. Cancer Res. 2010, 70: 2516-2527. 10.1158/0008-5472.CAN-09-3950
Article
CAS
PubMed
Google Scholar
Jin Y, Lu Z, Cao K, Zhu Y, Chen Q, Zhu F, Qian C, Pan J: The antitumor activity of homoharringtonine against human mast cells harboring the KIT D816V mutation. Mol Cancer Ther. 2010, 9: 211-223.
Article
CAS
PubMed
Google Scholar
Pan J, Quintas-Cardama A, Kantarjian HM, Akin C, Manshouri T, Lamb P, Cortes JE, Tefferi A, Giles FJ, Verstovsek S: EXEL-0862, a novel tyrosine kinase inhibitor, induces apoptosis in vitro and ex vivo in human mast cells expressing the KIT D816V mutation. Blood. 2007, 109: 315-322. 10.1182/blood-2006-04-013805
Article
CAS
PubMed
Google Scholar
Shi X, Jin Y, Cheng C, Zhang H, Zou W, Zheng Q, Lu Z, Chen Q, Lai Y, Pan J: Triptolide Inhibits Bcr-Abl Transcription and Induces Apoptosis in STI571-resistant Chronic Myelogenous Leukemia Cells Harboring T315I Mutation. Clin Cancer Res. 2009, 15: 1686-1697. 10.1158/1078-0432.CCR-08-2141
Article
CAS
PubMed
Google Scholar
Shambharkar PB, Blonska M, Pappu BP, Li H, You Y, Sakurai H, Darnay BG, Hara H, Penninger J, Lin X: Phosphorylation and ubiquitination of the IkappaB kinase complex by two distinct signaling pathways. EMBO J. 2007, 26: 1794-1805. 10.1038/sj.emboj.7601622
Article
CAS
PubMed
PubMed Central
Google Scholar
Quintas-Cardama A, Kantarjian H, Cortes J: Flying under the radar: the new wave of BCR-ABL inhibitors. Nat Rev Drug Discov. 2007, 6: 834-848. 10.1038/nrd2324
Article
CAS
PubMed
Google Scholar
Zeng G, Apte U, Micsenyi A, Bell A, Monga SP: Tyrosine residues 654 and 670 in beta-catenin are crucial in regulation of Met-beta-catenin interactions. Exp Cell Res. 2006, 312: 3620-3630. 10.1016/j.yexcr.2006.08.003
Article
CAS
PubMed
PubMed Central
Google Scholar
Lu Z, Jin Y, Chen C, Li J, Cao Q, Pan J: Pristimerin induces apoptosis in imatinib-resistant chronic myelogenous leukemia cells harboring T315I mutation by blocking NF-kappaB signaling and depleting Bcr-Abl. Mol Cancer. 2010, 9: 112- 10.1186/1476-4598-9-112
Article
CAS
PubMed
PubMed Central
Google Scholar
Shi X, Wang D, Ding K, Lu Z, Jin Y, Zhang J, Pan J: GDP366, a novel small molecule dual inhibitor of survivin and Op18, induces cell growth inhibition, cellular senescence and mitotic catastrophe in human cancer cells. Cancer Biol Ther. 2010, 9: 640-650. 10.4161/cbt.9.8.11269
Article
CAS
PubMed
Google Scholar
Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S: The protein kinase complement of the human genome. Science. 2002, 298: 1912-1934. 10.1126/science.1075762
Article
CAS
PubMed
Google Scholar
Larkin MA, Blackshields G, Brown NP, Chenna R, McGettigan PA, McWilliam H, Valentin F, Wallace IM, Wilm A, Lopez R: Clustal W and Clustal X version 2.0. Bioinformatics. 2007, 23: 2947-2948. 10.1093/bioinformatics/btm404
Article
CAS
PubMed
Google Scholar
Mol CD, Dougan DR, Schneider TR, Skene RJ, Kraus ML, Scheibe DN, Snell GP, Zou H, Sang BC, Wilson KP: Structural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase. J Biol Chem. 2004, 279: 31655-31663. 10.1074/jbc.M403319200
Article
CAS
PubMed
Google Scholar